Skip to content
DataLookout
Menu

NCT07052903

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 3 words
    • Enrollment increased: 1750 → 2250 participants
    • Study sites: 266 to 267
  2. Minor Study sites: 265 to 266
  3. Notable Eligibility criteria shortened, about 4 words
    • Trial sites expanded: 251 → 265 locations
    • Secondary endpoints: details revised at 1 of 4 entries
  4. Minor Trial sites expanded: 240 → 251 locationsv14
  5. Minor Enrollment increased: 1250 → 1750 participants
    • Trial sites expanded: 233 → 240 locations
    • Eligibility criteria revised
    v13
  6. Minor Trial sites expanded: 223 → 233 locationsv12
  7. Minor Trial sites expanded: 207 → 223 locationsv11
  8. Minor Trial sites expanded: 157 → 207 locationsv10
  9. Minor Study sites: 59 to 157v8
  10. Minor Study sites: 36 to 59v7
  11. Minor Study sites: 17 to 36v6
  12. Minor Study sites: 6 to 17v5
  13. Minor Study sites: 3 to 6v4
  14. Minor Study sites: 2 to 3v3
  15. Notable Eligibility criteria expanded, about 11 words
    • Start date changed from estimate of Jul 1, 2025 to Jul 2, 2025
    v2
  16. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Composite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)
Timeframe: Baseline to end of double-blind period (estimated 32 months, maximum 5 years)

Secondary (4)

Time to first CV event (CV hospitalizations and urgent HF visits) or all-cause mortality
All-cause mortality
Recurrent CV events (CV hospitalizations and urgent HF visits)
Change from baseline in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)

Arms and interventions

PlaceboPlacebo comparator

Participants will receive placebo administered subcutaneously (SC) once every 6 months (q6M) during the double-blind (DB) period, followed by nucresiran 300 mg administered SC q6M during the open-label extension (OLE) period.

Nucresiran 300 mgExperimental

Participants will receive nucresiran 300 mg administered SC Q6M during the DB period, followed by nucresiran 300 mg administered SC q6M during the OLE period.

Drugs: Nucresiran, Sterile Normal Saline (0.9% NaCl)

Sites

267 sites in 36 countries

United States 45, China 22, Japan 18, Spain 18, France 16, Italy 15, Brazil 12, Belgium 11, Germany 11, Argentina 8, Australia 8, Austria 7, Portugal 7, United Kingdom 6, Netherlands 5, South Korea 5, Switzerland 5, Canada 4, Czechia 4, Greece 4, Israel 4, Taiwan 4, Denmark 3, New Zealand 3, Sweden 3, Turkey (Türkiye) 3, Chile 2, Hungary 2, Ireland 2, Malaysia 2, Norway 2, Romania 2, Hong Kong 1, Mexico 1, Poland 1, Slovakia 1